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Background: In the present study, extracts prepared from the leaves of Rhus parviflora Roxb. (Anacardiaceae) were
evaluated for their anti-HIV activity, which have been traditionally used for the treatment of neurological disorders
such as anxiety, insomnia and epilepsy.
Methods: Aqueous and 50% ethanolic extracts prepared from leaves of the plant were tested for their cytotoxicity
and anti-HIV property using reporter gene based assays as well as human peripheral blood lymphocytes (PBLs).
Further these extracts were evaluated for their ability to inhibit HIV-1 reverse transcriptase (RT) and protease activity.
Safety profile of the extracts was determined on viability of Lactobacillus sp., secretion of pro-inflammatory
cytokines by vaginal keratinocytes and transepithelial resistance.
Results: Both aqueous (IC50 = 15 μg/ml) and 50% ethanolic (IC50 = 26 μg/ml) extracts prepared from leaves of
R. parviflora showed anti-HIV activity in TZM-bl cells wherein the virus was treated with the extracts prior to
infection. Further, both the extracts also inhibited virus load in HIV infected CEM-GFP cells and human PBLs. The
anti-HIV activity is mediated through inhibition of HIV-1 protease activity. Both the extracts did not disturb the
integrity of monolayer formed by intestinal epithelial Caco-2 cells. The extracts when tested up to 100 μg/ml
did not significantly reduce the viability of L. plantarum, L. fermentum, L. rhamnosus and L. casei. The extracts
(100 μg/ml) did not reveal any cytotoxic effect on vaginal keratinocytes (Vk2/E6E7). Levels of pro-inflammatory
cytokines secreted by Vk2/E6E7 cells treated with both the plant extracts were within the non-inflammatory range.
Conclusions: The studies reported herein showed in vitro anti-HIV activity and preliminary safety profile of the
extracts prepared from the leaves of R. parviflora.
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Pro-inflammatory cytokinesBackground
Acquired Immunodeficiency Syndrome (AIDS), an im-
munological disorder characterized by abnormalities of
immunoregulation and opportunistic infections, caused
by the human immunodeficiency virus (HIV) is one of
the major public health problems [1]. Treatment of HIV
infected patients with currently available highly active
anti-retroviral (HAART) drugs though successful in re-
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reproduction in any medium, provided the orvarious side effects, including emergence of drug resist-
ant HIV strains [2-6]. Hence, it is imperative to discover
novel anti-HIV agents from natural sources that may
have lesser side effects. Various studies have shown anti-
HIV properties of the extracts prepared from variety of
plants [7-9]. The plant extracts or purified phytochemi-
cals may exhibit anti-HIV activity by inhibiting virus
entry/fusion, HIV-1 reverse transcriptase (RT), protease
or its integrase activity [10-13]. Further, to prevent sex-
ual transmission of HIV, microbicides with anti-HIV
properties have been proposed that can be applied topic-
ally before sexual act [14].
Rhus parviflora Roxb. (Anacardiaceae) is known as
‘Tintidika’ in Sanskrit language, widely distributed intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tudinal range of 700–1100 m [15]. It is recorded in
Ayurvedic pharmacopoeia as having therapeutic uses for
Vāta vikāra, the complications related to neurological
disorders including anxiety, insomnia, epilepsy, and
rheumatoid arthritis [16]. In Nepal, fruits of R. parviflora
are also used for human consumption and decoction of
fruit or stem bark used to cure dysentery [17,18]. Bark
extract is applied externally on wounds and small twigs
are used for cleaning teeth [19]. In some tribal areas, in-
fusions of leaves were given in cholera [20]. Phytochemi-
cals like gallic acid, some flavones viz., rutin, myricetin,
quercetin, myricitrin, quercitrin, kampferol and some
glycosides (isorhamnetin-3-α-L-arabinoside) have been
isolated from the plant [16,21].
The current study was undertaken to evaluate anti-HIV
property of the aqueous and 50% ethanolic extracts pre-
pared from leaves of R. parviflora using in vitro assays. Fur-
ther, pre-clinical safety profile of these extracts with respect
to viability of Lactobacillus sp., epithelial cell monolayer in-
tegrity and secretion of pro-inflammatory cytokines by vagi-
nal keratinocytes has been studied.
Methods
Collection of plant material
Fresh leaves (1 kg) of the wild R. parviflora plant were col-
lected in May 2008 from Khairna, Nainital, India (Acces-
sion Number-NBRH16) and specimen has been submitted
to Herbarium of National Botanical Research Institute
(NBRI), Lucknow, India. The plant material was collected
and identified by Dr. A. K. S. Rawat, who is a taxonomist/
botanist, Pharmacognosy Department, NBRI, Lucknow.
The leaves were air and shade dried, grinded and strained
through a mesh (size 30, mesh opening 0.5 mm).
Preparation of 50% ethanolic and aqueous extracts
To prepare 50% ethanolic extract, R. parviflora leaves
powder (100 gm) was charged in a percolator, treated
with ethanol: water (500 ml, 1:1 v/v) and left overnight
at 25-30°C. The percolate (300 ml) was drained and the
marc extracted thrice by cold percolation, each time
with 500 ml of ethanol: water (1:1 v/v) and the com-
bined percolate (1200 ml) was evaporated at 40-45°C
under vacuum to concentrate the extract up to 80 ml.
The concentrated 50% ethanolic extract was lyophilized
at −20 to −40°C to afford 8-10% dried extract.
To prepare aqueous extract, R. parviflora leaves pow-
der (100 gm) was treated with 500 ml of MilliQ water at
65-75°C for 6–8 h. The hot water extract was filtered
through Whatman filter paper number 1. The marc was
extracted thrice, each time with 500 ml of water at 60-75°
C. The combined filtrate (1200 ml) was distilled at 45-50°
C under vacuum to afford concentrated aqueous extract
up to 70 ml. The extract was subsequently, lyophilizedat −20 to −40°C to afford 9-11% dried extract. Both aque-
ous and 50% ethanolic extracts were characterized by High
Performance Liquid Chromatography (HPLC), wherein
20 μl of the respective extract (1 mg/ml) was resolved by
C18 column (Cap cell Pak C18, Phenomenex, CA, USA)
using an isocratic acetonitrile and water supplemented
with 10 mM formic acid (35:65; v/v), at a flow rate of
0.4 ml/min. The elution profile was monitored at 280 nm.
Cell maintenance and HIV
Anti-HIV assays were performed using TZM-bl [recom-
binant HeLa cell line expressing high levels of CD4, HIV-1
co-receptors CCR5 & CXCR4 with β-galactosidase and lu-
ciferase reporter genes under HIV-1 long terminal repeat
(LTR) promoter] and CEM-GFP [a CD4+ T-lymphocytic
reporter cell line expressing green fluorescent protein
(GFP) under HIV-1 LTR promoter] reporter cells. TZM-bl
cells were maintained in Dulbecco's modified Eagle’s
medium (DMEM; Sigma-Aldrich Inc., St. Louis, MO,
USA) supplemented with 10% fetal bovine serum (FBS;
Biological Industries, Kibbutz Beit Haemek, Israel) and
antibiotic-antimycotic cocktail [Penicillin (100 units/ml),
Streptomycin (100 μg/ml) and Amphotericin B (250 ng/
ml); Pen-Strep-Ampho sol, Biological Industries] whereas,
CEM-GFP cells in RPMI-1640 medium (Sigma-Aldrich
Inc.) supplemented with 10% FBS, G418 (500 μg/ml;
Gibco, Grand Island, NY, USA) and antibiotic-antimycotic
cocktail as used for TZM-bl cells [22]. Vk2/E6E7 cells (im-
mortalized cell line derived from the normal human vagi-
nal mucosa), a generous gift from Dr. Raina Fichorova
(Brigham and Women’s Hospital, Boston, MA, USA), were
cultured in Keratinocyte serum-free medium (ker-sfm)
supplemented with bovine pituitary extract and epidermal
growth factor (Gibco-Invitrogen, Carlsbad, CA, USA).
Caco-2 cells (American Type Culture Collection, Manassas,
VA, USA) were cultured in RPMI medium, supplemented
with 10% FBS and previously used antibiotic-antimycotic
cocktail. Saquinavir (Catalog Number 4658) was obtained
from AIDS Research and Reference Reagent Program, Div-
ision of AIDS, National Institute of Allergy and Infectious
Diseases, USA.
HIV-1NL4.3 was prepared by transfection of HEK-293T
cells with pNL4.3 plasmid (Catalog number 114; AIDS Re-
search and Reference Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious Diseases,
USA) using CaPO4 method as described previously [23].
Cytotoxicity assay using MTT
The cytotoxicity of plant extracts on various cell lines
was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma-Aldrich Inc.] assay
[24]. In brief, cells were seeded (6 × 103 adherent cells/
well; 5 × 104 suspension cells/well) in 96-well cell cul-
ture plates (Greiner Bio-One, GmbH, Frickenhausen,
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atmosphere of 5% CO2. After 24 h, cells were treated
with varying concentrations of the extracts ranging from
10–400 μg/ml, for the duration as used to determine the
anti-HIV activity [TZM-bl cells - 48 h; CEM-GFP cells -
8 days with a change of medium on 5th day and human
peripheral blood lymphocytes (PBLs) for 5 days]. Nega-
tive control included cells treated with solvent/medium.
After incubation, cell viability was assessed by adding
20 μl MTT (5 mg/ml in 50 mM PBS) per well and incu-
bated at 37°C for 3 h followed by addition of MTT solvent
(100 μl/well; 20% SDS and 50% dimethyl formamide in
50 mM PBS) [24]. The absorbance (OD) was read at
570 nm with reference filter at 690 nm. Experiments were
performed in duplicates and percent viability was calcu-
lated by dividing the OD obtained in treatment group by
OD of untreated cell control multiplied by hundred.
Anti-HIV activity using TZM-bl cells
In TZM-bl cells-based assay, HIV-1NL4.3 viral strain at a
multiplicity of infection (MOI) of 0.05 was treated with
varying concentrations (2–50 μg/ml) of extracts for 1 h
at 37°C. Subsequently, HIV-1 pretreated with plant ex-
tracts was added to TZM-bl cells (4 × 104/well; seeded
on the previous day in 24-well plate) and incubated for
4 h. Subsequently, cells were washed with cold 50 mM
PBS, fresh culture medium with extracts added and fur-
ther incubated for 48 h in humidified atmosphere of 5%
CO2 at 37°C. Azidothymidine (AZT; Sigma-Aldrich Inc.)
was used as positive reference control. After incubation,
cells were washed twice with PBS and lysed with 1X lysis
buffer (Promega Corporation, Madison, WI, USA).
Supernatant was collected and luciferase activity was
measured using white optiplate in the Fluorimeter
(BMG Labtech GmbH, Offenberg, Germany). The re-
sults were expressed as percentage inhibition, calculated
by taking the luminescence in experimental group di-
vided by the luminescence in infected cells in absence of
test extracts/AZT multiplied by hundred. Percent inhib-
ition was calculated by subtracting the above value from
hundred.
Inhibition of HIV infection using CEM-GFP cells-based
assay
CEM-GFP cells (5 × 106) were infected with HIV-1NL4.3
virus at an MOI of 0.05 in presence of polybrene (2 μg/
ml) for 4 h at 37°C with intermittent mixing as described
previously [25]. Post-infection, the cells were washed
twice with serum free RPMI-1640 medium and were
seeded (2.0 × 105/well) in a 24-well plate. Plant extracts
at varying concentrations (1–50 μg/ml) were added to
their respective wells. AZT was used as a positive con-
trol whereas solvents used to prepare extracts were used
as negative controls. On 5th day, 0.4 ml of cell suspensionwas removed from each well, 1 ml fresh medium along
with the extracts was added to the wells and plate was fur-
ther incubated. On 8th day, 100 μl supernatant was col-
lected for p24 analysis. For GFP estimation, cells were
lysed with 150 μl of 1X Promega cell culture lysis buffer
and lysate was centrifuged at 9000 × g for 10 min at 4°C.
The supernatant (100 μl/well) was transferred to black
optiplate and the absorbance was measured at an excita-
tion wavelength of 485 nm and emission at 520 nm using
Fluorimeter (FLUostar Optima, BMG Labtech, Germany).
The results were expressed as percentage inhibition, calcu-
lated by taking the GFP fluorescence in experimental
group divided by GFP fluorescence in infected cells in the
absence of test extract/AZT multiplied by hundred. Per-
cent inhibition was obtained by subtracting the above
value from hundred.
Anti-HIV assay using human peripheral blood
lymphocytes (PBLs)
All experiments using human blood cells were carried out
under informed consent of the blood donors and following
the clearance from the Institutional Bio-safety and Human
Ethical Committee. Blood (5 ml) was taken from
healthy HIV sero-negative donors and peripheral blood
lymphocytes (PBLs) were isolated using Ficoll density
gradient method. Cells (2 × 106 cells/ml) were stimu-
lated for 3 days with 3 μg/ml phytohemagglutinin
(PHA-P; Sigma-Aldrich Inc.) and after stimulation
washed twice to remove PHA-P. Stimulated cells were
infected by HIV-1NL4.3 at an MOI of 0.05, in presence
of IL-2 (10 U/ml) for 4 h as described for CEM-GFP
cells. Infected cells were washed twice with plain
medium to remove the unbound virus and seeded in
96-well plate (5 × 104 cells/well), in 200 μl of RPMI
medium supplemented with 10% FBS and 10 U/ml re-
combinant human IL-2. The extracts (20 μl/well) at
varying concentrations, diluted in culture medium,
were added in duplicate. Cells were cultured at 37°C,
5% CO2 and culture supernatant was collected on day 5
for p24 analysis.
The viral load in the supernatant (diluted 1:10 or 1:20)
of CEM-GFP cells as well as human PBLs treated
with plant extracts was measured using ELISA kits
(SAIC-Frederick Inc., NCI-Frederick, USA; XpressBio, Life
Science Products, MD, USA) for p24 estimation, following
the instructions of the manufacturer. The non-specific in-
hibition of p24 binding to its antibody in ELISA in the
presence of plant extracts was taken into account while
calculating p24 concentration in the culture supernatants.
Results were expressed as percent inhibition in virus load
calculated by dividing the p24 concentration in the pres-
ence of plant extracts/AZT by p24 value observed in nega-
tive control, multiplied by hundred and the obtained value
was subtracted from hundred.
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The inhibitory activity of plant extracts on HIV-1 RT was
determined by commercial kit (Roche Applied Sciences,
Mannheim, Germany) as per the manual’s instructions. In
addition, effect of plant extracts on HIV-1 protease activity
was also determined using kit (Anaspec, CA, USA) as per
the manufacturer’s instructions.
Estimation for pro-inflammatory cytokines secreted by
human cervico-vaginal keratinocytes
To study the toxic and inflammatory responses of the plant
extracts, a human cervico-vaginal keratinocyte cell line
(Vk2/E6E7) was used [26]. Cells (6.0 × 103 cells/well) were
seeded in 96-well culture plate and incubated in humidified
atmosphere of 5% CO2 at 37°C for 24 h. After incubation,
cells were treated with plant extracts (100 μg/ml) for 24 h
and culture supernatant was collected for various cytokines
quantiation using BDTM Cytometric Bead Array kit (BD
FACSCanto Flow Cytometer; BD Biosciences Pharmigen,
San Diego, CA, USA). The kit allows simultaneous quanti-
fication of interleukin (IL)-1β, IL-6, IL-8 and tumor necro-
sis factor (TNF). The cytokine bead assay was performed
according to the manufacturer's specifications and data
analysis was done using BD FACSDiva software. In
addition, Vk2/E6E7 cells viability after 24 h treatment with
test extracts was also determined by MTT assay as de-
scribed above.
Transepithelial resistance (TER) measurement
Effect of the plant extracts on epithelial cells integrity
(transepithelial resistance; TER) was measured using
voltmeter. Caco-2 cells (5 × 105 cells/well) were grown
in transwells and culture medium was dispensed in the
basolateral compartment of each well. The cells were
allowed to grow for 36–48 h in 5% CO2 at 37°C. Resist-
ance was measured using Millicell–ERS voltmeter (EMD
Millipore Corporation, Billerica, MA, USA) each day
until resistance reached plateau. After formation of
monolayer, extracts (50 μg/ml) was added in the culture
medium and cells further incubated in humidified at-
mosphere of 5% CO2 at 37°C. Resistance was measured
at intervals of 0.5, 1, 2, 4, 8 and 24 h (cells were incu-
bated in 5% CO2 at 37°C in between each reading).
Effect of plant extracts on the viability of lactobacilli
Various lactobacilli strains such as Lactobacillus casie
(MTCC 1423), L. fermentum (MTCC 903), L. plantarum
(MTCC 4462) and L. rhamnosus (MTCC 1408) were
obtained from Institute of Microbial Technology,
Chandigarh, India and cultured in MRS broth (HiMedia,
Mumbai, India). The cytotoxicity of plant extracts on lacto-
bacilli was assessed by MTT assay as described previously
[27,28]. In brief, bacterial density was adjusted to an OD of
0.06 at a wavelength of 670 nm i.e. approximately108 CFU/ml. Extracts were administered at concentrations
ranging from 3.125-100 μg/ml into 96-well plates along
with 30 μl of bacterial suspension. Final volume was made
up to 100 μl using MRS broth. Negative control included
cells treated with solvent/medium and Saquinavir, a known
HIV-1 protease inhibitor was used as reference control.
After incubation for 24 h at 37°C, 10 μl of MTT (5 mg/ml
in 50 mM PBS; Sigma-Aldrich Inc.) was added to each well
containing microbial inoculums and plant extracts. Plates
were incubated for 3 h at 37°C, followed by centrifugation
at 2500 g for 10 min. Supernatants were aspirated and
100 μl of acid-isopropanol (5 ml of 1 N HCl in 95 ml of
isopropanol) was added to each well. Optical density was
measured using micro plate spectrophotometer (ELX
800MS; BioTek Instrument Inc., Vermont, USA) at
540 nm using reference filter at 690 nm. Percent viability
was calculated by dividing the absorbance of treated cells
to untreated cells multiplied by hundred.
Statistical analysis
Analyses of concentration-response data were performed
by the use of nonlinear curve-fitting program Prism
(Graph Pad Software Inc., CA, USA) to determine CC50
and IC50 values. The results were average of 2–3 inde-
pendent experiments. The statistical significance of the
values obtained in different assays in presence of varying
concentrations of the plant extract with respect to un-
treated group was calculated using one way ANOVA. A p-
value of <0.05 was considered to be statistically significant.
Results and discussion
With the aim to discover new plants as a source for pre-
vention of HIV infection, aqueous and 50% ethanolic ex-
tracts prepared from leaves of R. parviflora were evaluated
for anti-HIV activity using reporter gene-based cells assays
and human PBLs. The safety of the extracts with respect
to the effect on epithelial cell integrity, adverse effect on
the viability of lactobacilli as well as production of pro-
inflammatory cytokines by vaginal keratinocytes was
assessed. Analyses of the aqueous and 50% ethanolic ex-
tracts prepared from the leaves of R. parviflora by HPLC
revealed these to be a complex mixture of phytochemicals
(Additional file 1: Figure S1A, S1B). It is likely that the
aqueous extract will have preponderance of polar com-
pounds whereas 50% ethanolic extract will have higher
concentration of non-polar compounds.
Aqueous and 50% ethanolic extracts from leaves of R.
parviflora inhibit HIV-1 infection
The inhibitory activity of the extracts against HIV infec-
tion is sometimes, a result of their toxic effects and con-
sequently might result in an erroneous conclusion.
Hence to exclude the non-specific antiviral effect, the
toxicity of plant extracts on TZM-bl and CEM-GFP cells
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ethanolic as well as aqueous extracts prepared from
leaves of R. parviflora were > 331 μg/ml on TZM-bl cells
and >196 μg/ml on CEM-GFP cells (Table 1). Both aque-
ous (IC50; 15 μg/ml) and 50% ethanolic extract (IC50;
26 μg/ml) showed dose dependent inhibition in HIV-1
infection using TZM-bl cell-based assay (Table 1). Treat-
ment of HIV-1 infected CEM-GFP cells with the 50%
ethanolic as well as aqueous extracts of the leaves of R.
parviflora also showed a dose dependent inhibition of
HIV infection with IC50 values of 29 and 65 μg/ml, re-
spectively (Table 1). Both the extracts reduced the virus
released by infected CEM-GFP cells as estimated by p24
in the culture supernatants collected from the infected
cells (Figure 1). The higher efficacy of the extracts in
TZM-bl cells as compared to CEM-GFP cells-based assay
may be due to an additional step of virus pre-treatment
with extracts in TZM-bl cells-based assay format and
hence suggests the presence of additional virucidal phyto-
chemicals. The therapeutic index (TI) of a drug is the ratio
between the toxic and the therapeutic dose and is used as
a measure of its relative safety. The TI values of the ex-
tracts were in a range of 6.8 to 25.5 (Table 1).
Furthermore, apart from the usage of reporter-gene
based assays, the inhibitory activity of the extracts from R.
parviflora was also assessed using activated human lym-
phocytes (PBLs; biological targets of HIV including CD4+
T cells, monocytes, dendritic cells, etc.) from blood of HIV
seronegative donors. The extracts were non-toxic to PBLs
up to a concentration of 100 μg/ml (data not shown).
There was a dose-dependent inhibition in p24 secretion
by infected PBLs that were treated with 50% ethanolic and
aqueous extracts prepared from leaves of R. parviflora
(Figure 2). The present study demonstrates for the first
time that leaves extracts prepared from R. parviflora
display inhibitory effect on HIV-1 replication. Several phy-
tochemicals such as gallic acid, myricetin, quercetin,
kampferol and different glycosides have been reported toTable 1 In vitro cytotoxicity and anti-HIV activity of the
extracts derived from leaves of R. parviflora using TZM-bl
and CEM-GFP cells
Plant extract CC50 (μg/ml)* IC50 (μg/ml)* TI
TZM-bl cells
50% Ethanolic extract 331 26 12.7
Aqueous extract 383 15 25.5
CEM-GFP cells
50% Ethanolic extract 196 29 6.8
Aqueous extract 643 65 9.9
*CC50: The cytotoxic concentration of the extracts that caused the reduction of
viable cells by 50%. All data presented are averages of duplicate experiments.
*IC50: The concentration of the extracts that resulted in 50% inhibition in HIV
infection. All data presented are averages of duplicate experiments.
TI: Therapeutic index is CC50/IC50.be present in R. parviflora [16,21]. Medicinally important
compounds like gallic acid, quercetin, kampferol, glyco-
sides etc. from other plants have been reported for their
anti-HIV activity suggesting that the presence of these
compounds may be responsible for the inhibition of HIV
infection by R. parviflora leaves extracts [29,30]. However,
further studies for identification and characterization of
the anti-HIV active compounds from leaves extract of this
plant are still required.
Anti-HIV activity of the extracts from R. parviflora
mediated by inhibiting HIV-1 protease activity
Since HIV-1 is a retrovirus, virally encoded enzyme re-
verse transcriptase (RT) that catalyzes the conversion of
viral RNA to proviral DNA is an important target where
the extract may act to inhibit HIV infection. For this,
the RT activity was evaluated in presence and absence of
extract using a kit (Roche Diagnostics). No inhibition in
RT activity was observed in presence of both the extracts
(50 μg/ml) as compared to Nevirapine (1 μM) used as a
positive control with ~90% inhibition (data not shown).
These results imply that anti-HIV activity of the leaves
extract of R. parviflora is not mediated by inhibition of
HIV-1 RT activity, rather the extract may act at different
steps of HIV life cycle.
HIV-1 protease is another important enzyme of the
HIV life cycle acting at post-entry level. Protease influ-
ences the viral components to associate with host cell
membrane which then buds off as immature virions.
Protease activity continues after detachment from the
host cell to ensure maturation into a fully infectious vir-
ion. The 50% ethanolic and aqueous leaves extracts of R.
parviflora were evaluated for their effect on HIV-1 pro-
tease activity. Both these extracts inhibited HIV-1 prote-
ase activity in a dose dependent manner when tested at
10, 20 and 50 μg/ml. A maximum inhibition of >65%
was shown by both the extracts at 50 μg/ml (Figure 3).
Hence, HIV-1 protease inhibition is one of the mode by
which the extracts prepared from leaves of R. parviflora
inhibited HIV infection. However, a higher degree of in-
hibition of HIV-1 infection by these extracts might be
attributed to the presence of several phytochemicals that
could work through interference at other steps of virus
life cycle.
Extracts derived from R. parviflora has no adverse effect on
trans-epithelial cells resistance and viability of lactobacilli
Integrity of the epithelial cell lining of the reproductive
tract is critical for the prevention of sexual transmission
of HIV. The maintenance of an intact and polarized
monolayer in presence of any topical agent used as mi-
crobicide indicates their safety on cervical and colorectal
tissues [31]. The integrity of the intact epithelium as an





































Figure 1 Reduction in virus load by leaves extracts of R. parviflora using CEM-GFP cells. Cells were infected with HIV-1NL4.3 (0.05 MOI) and
treated with extracts at various concentrations followed by 8 day incubation. Culture supernatant was collected on 8th day for p24 estimation by
ELISA. AZT (10 μM) was used as positive control that reduced p24 level by 97%. Data is represented as mean ± SE of three independent
experiments performed in duplicates. Statistical significance between the extract treated groups as compared to untreated control is shown by
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aqueous extracts were screened for their toxicity on Caco-
2 cells, prior to TER measurement. TER was performed at
a non-toxic concentration of the extracts (50 μg/ml). The
extracts were added after the cells established a confluent
monolayer, followed by TER measurement for 24 h. The
non-toxic concentration of the extracts did not reduce the
TER significantly (p > 0.05) as compared to the untreated
controls. After 24 h of application, the TER value was
same as of untreated cells except for Triton-X that led to a







































Figure 2 Anti-HIV activity of leaves extracts of R. parviflora on
infected human peripheral blood lymphocytes (PBLs). Cells were
infected with HIV-1NL4.3 (0.05 MOI) and treated with extracts at
various concentrations followed by 5 days incubation. Culture
supernatant was collected for p24 estimation by ELISA. AZT (10 μM)
was used as positive control that reduced p24 level by 33%. Data is
represented as mean ± SE of three independent experiments
performed in duplicates. Statistical significance between the extract
treated groups as compared to untreated control is shown by
asterisk (*p < 0.05; **p < 0.01; ***p < 0.001).its application (Figure 4). Overall, the non-toxic concen-
tration of the extracts of R. parviflora did not affect the
TER and hence may be suitable candidates for topical
application.
Lactobacillus sp. are the dominant members of the hu-
man vaginal microflora, where they play a protective role





































Figure 3 Inhibitory effect of the extracts prepared from leaves
of R. parviflora on HIV-1 protease activity. Inhibition of HIV-1
protease by 50% ethanolic and aqueous extracts prepared from
leaves of R. parviflora was determined by a commercial kit.
Experiments were performed using both positive (HIV-1 protease
with pepstatin treatment) as well as negative controls (HIV-1
protease without treatment). Data is expressed as percent inhibition
of HIV-1 protease activity determined by dividing the difference in
fluorescent intensity of experimental and negative control by
negative control followed by multiplication with 100. Data is
represented as mean ± SE of three independent experiments.
Statistical significance between the extract treated groups as
compared to untreated enzyme control group is presented by




















Figure 4 Effect of the extracts of R. parviflora on epithelial
monolayer integrity. Caco-2 cells were grown in transwell supports
until they formed stable monolayer. Plant extracts or vehicle control
were added to the apical chamber at t = 0 and resistance was
measured at 0.5, 1, 2, 4, 8 and 24 h. As toxicity reference control
Triton-X (10%) was added to the indicated apical chambers whereas
the test extracts were evaluated at 50 μg/ml. Data shown represent


























Figure 5 Effect of leaves extracts derived from R. parviflora on
different Lactobacillus strains. Various lactobacilli strains (108 CFU/
ml) were cultured in presence or absence of various extracts/
saquinavir (a commercially available HIV-1 protease inhibitor used as
a reference control) at 100 μg/ml, for 24 h at 37°C and followed-up
by viability assessment using MTT assay as described in Methods.
Values are expressed as percent viability determined by dividing the
absorbance of treated cells to untreated cells followed by
multiplication with hundred. Data is represented as mean ± SE of
three independent experiments performed in duplicates. Statistical
significance of either the increase or decrease in viability of
lactobacilli treated with either plant extracts or saquinavir as
compared to untreated lactobacilli is shown by alphabets (ap < 0.05).
Table 2 Pro-inflammatory cytokines secretion by vaginal
keratinocytes (Vk2/E6E7) after treatment with extracts





IL-1β IL-6 IL-8 TNF
Control 2.0 ± 0.2 119.0 ± 9.1 288.0 ± 5.3 1.1 ± 0.6
50% Ethanolic extract 1.7 ± 0.0 164.4 ± 10.0 10.4 ± 1.0* 1.7 ± 0.3
Aqueous extract 1.6 ± 0.6 126.7 ± 9.4 241.5 ± 10.2 1.5 ± 0.4
#100 μg/ml for 24 h.
*p < 0.001 as compared to IL-8 concentration in the control group.
Modi et al. BMC Complementary and Alternative Medicine 2013, 13:158 Page 7 of 9
http://www.biomedcentral.com/1472-6882/13/158of HIV virus [32], so it is essential that the extracts from R.
parviflora should be non-toxic to their growth. Incubation
of Lactobacillus casei, L. fermentum, L. plantarum and L.
rhamnosus with aqueous as well as 50% ethanolic extracts
up to 100 μg/ml revealed no cytotoxic effects. Viability of
different lactobacilli strains at 100 μg/ml of different ex-
tracts/saquinavir is shown in Figure 5. On comparison with
saquinavir, a commercially used protease inhibitor, less than
75% viable population of L. fermentum and L. rhamnosus
was recorded. Natural barriers of HIV are low pH, presence
of lactobacilli, intact epithelial surface and the mucosal im-
mune system of the genital tract [33,34]. Therefore, in vitro
toxicity on lactobacilli may provide an effective and inex-
pensive method to evaluate the safety of candidate
microbicides in a preclinical setting. R. parviflora have high
levels of flavonoids and polyphenols [16] and according to
previous studies, growth of lactobacilli are stimulated by
catechins and polyphenol compounds [35,36].
No significant increase in pro-inflammatory cytokines
observed in human vaginal derived cells after treatment
with extracts prepared from R. parviflora
While considering these extracts as candidates to be used
for prevention of sexual transmission of HIV, their effect
on primary vaginal keratinocytes viability is highly rele-
vant, as vaginal epithelial cells form a part of the physical
barrier that may impede the passage of cell-free or cell as-
sociated HIV-1 into sub epithelial tissues. Clinical trials
based on N-9-containing microbicidal products have
raised concerns that disruption of the cervicovaginal epi-
thelium as well as rise in pro-inflammatory cytokines se-
cretion by spermicides or microbicides application may
increase the susceptibility to HIV-1 infection by providinga direct portal of entry for the virus to subcutaneous tis-
sues and/or by recruiting HIV-1-susceptible immune cells
to the genital tissues [37-39]. Therefore, ruling out an in-
crease of pro-inflammatory cytokines secretion after appli-
cation of the plant extracts on vaginal surface was
particularly important. Vk2/E6E7 cells are immortalized
human vaginal epithelial cells that proved to be an adequate
model for studying the vaginal responses to topical agents
[26]. No cytotoxicity was observed for Vk2/E6E7 cells,
when these cells were cultured with the extracts up to
100 μg/ml for 24 h. The concentrations of IL-1β, IL-6, IL-8
and TNF were determined in the culture supernatants. As
compared to the control, a decrease in the concentration of
IL-1 β as well as IL-8 was observed subsequent to treat-
ment of Vk2/E6E7 cells with both the extracts. However,
treatment with 50% ethanolic extract led to a significant
(p < 0.001) decrease in IL-8 secretion (Table 2). An increase
in the secretion of IL-6 and TNF was observed which was
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[40]. Thus, the extracts from R. parviflora appear to be
safe and may be useful candidate to be developed as
microbicides.
Conclusions
In addition to its other traditional uses, the extracts pre-
pared from R. parviflora have anti-HIV-1 property, which
may be mediated through inhibition of HIV-1 protease ac-
tivity. The extracts have no adverse effect on the growth
of lactobacilli, epithelial monolayer integrity and subse-
quent to treatment with the extracts, pro-inflammatory
cytokines levels are within the non-inflammatory range.
These observations are encouraging and further safety and
efficacy studies in vivo may be undertaken to explore po-
tential of the extracts prepared from R. parviflora for pre-
vention of HIV sexual transmission.
Additional file
Additional file 1: Figure S1. HPLC profiles of aqueous and 50%
ethanolic extracts prepared from leaves of R. parviflora. HPLC was
performed using C18 column (4.6 mm × 250 mm) at a flow rate of
0.4 ml/min. An isocratic elution (acetonitrile-water with 10 mM of formic
acid; 35:65) was performed and peaks were monitored at 280 nm. Figure
A represents HPLC profile of aqueous extract (20 μg) and Figure B
represents profile of 50% ethanolic extract (20 μg).
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